BGB 15025

CAS No. 2766481-17-6

BGB 15025( ——— )

Catalog No. M39443 CAS No. 2766481-17-6

HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC50 of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BGB 15025
  • Note
    Research use only, not for human use.
  • Brief Description
    HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC50 of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases.
  • Description
    HPK1-IN-32 is a potent and selective HPK1 inhibitor with an IC50 of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    HPK1
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    2766481-17-6
  • Formula Weight
    536.64
  • Molecular Formula
    C28H37FN8O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 50 mg/mL (93.17 mM; ultraphonic; )
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sanjia XU, et al. 3-(1h-pyrazol-4-yl)oxypyrazin-2-amine compounds as hpk1 inhibitor and use thereof. Patent. WO2022068848.
molnova catalog
related products
  • AtPep3 TFA

    AtPep3 is a hormone-like peptide that plays a role in the salinity stress tolerance of plants.

  • IPSU

    IPSU is an antagonist of OX2 receptor. IPSU Exhibits approximately six-fold selectivity for OX2 versus OX1 receptors.

  • L-JNKI-1

    L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.